160 related articles for article (PubMed ID: 23877991)
81. Real-world evidence: the devil is in the detail.
Gokhale M; Stürmer T; Buse JB
Diabetologia; 2020 Sep; 63(9):1694-1705. PubMed ID: 32666226
[TBL] [Abstract][Full Text] [Related]
82. The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study.
Pradhan R; Yin H; Yu OHY; Azoulay L
Drug Saf; 2020 Feb; 43(2):103-110. PubMed ID: 31838652
[TBL] [Abstract][Full Text] [Related]
83. Methodological considerations when analysing and interpreting real-world data.
Stürmer T; Wang T; Golightly YM; Keil A; Lund JL; Jonsson Funk M
Rheumatology (Oxford); 2020 Jan; 59(1):14-25. PubMed ID: 31834408
[TBL] [Abstract][Full Text] [Related]
84. The importance and implications of comparator selection in pharmacoepidemiologic research.
D'Arcy M; Stürmer T; Lund JL
Curr Epidemiol Rep; 2018 Sep; 5(3):272-283. PubMed ID: 30666285
[TBL] [Abstract][Full Text] [Related]
85. Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study.
Borgquist S; Rosendahl AH; Czene K; Bhoo-Pathy N; Dorkhan M; Hall P; Brand JS
Breast Cancer Res; 2018 Aug; 20(1):93. PubMed ID: 30092829
[TBL] [Abstract][Full Text] [Related]
86. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
[TBL] [Abstract][Full Text] [Related]
87. Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats.
Mori Y; Ko E; Furrer R; Qu LC; Wiber SC; Fantus IG; Thevis M; Medline A; Giacca A
Endocr Connect; 2018 May; 7(5):739-748. PubMed ID: 29692348
[TBL] [Abstract][Full Text] [Related]
88. Genome-Wide Analyses Identify Filamin-A As a Novel Downstream Target for Insulin and IGF1 Action.
Aizen D; Pasmanik-Chor M; Sarfstein R; Laron Z; Bruchim I; Werner H
Front Endocrinol (Lausanne); 2018; 9():105. PubMed ID: 29615978
[TBL] [Abstract][Full Text] [Related]
89. Considerations for Pharmacoepidemiological Studies of Drug-Cancer Associations.
Pottegård A; Friis S; Stürmer T; Hallas J; Bahmanyar S
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):451-459. PubMed ID: 29265740
[TBL] [Abstract][Full Text] [Related]
90. Utilization of fetal fibronectin testing and pregnancy outcomes among women with symptoms of preterm labor.
Blackwell SC; Sullivan EM; Petrilla AA; Shen X; Troeger KA; Byrne JD
Clinicoecon Outcomes Res; 2017; 9():585-594. PubMed ID: 29042802
[TBL] [Abstract][Full Text] [Related]
91. Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study.
But A; De Bruin ML; Bazelier MT; Hjellvik V; Andersen M; Auvinen A; Starup-Linde J; Schmidt MK; Furu K; de Vries F; Karlstad Ø; Ekström N; Haukka J
Diabetologia; 2017 Sep; 60(9):1691-1703. PubMed ID: 28573394
[TBL] [Abstract][Full Text] [Related]
92. Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.
Hong JL; Jonsson Funk M; Buse JB; Henderson LM; Lund JL; Pate V; Stürmer T
Epidemiology; 2017 May; 28(3):446-454. PubMed ID: 28166101
[TBL] [Abstract][Full Text] [Related]
93. Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors.
Htoo PT; Buse JB; Gokhale M; Marquis MA; Pate V; Stürmer T
Eur J Clin Pharmacol; 2016 Aug; 72(8):1013-23. PubMed ID: 27165664
[TBL] [Abstract][Full Text] [Related]
94. Insulin glargine use and breast cancer risk: Associations with cumulative exposure.
Peeters PJ; Bazelier MT; Leufkens HG; Auvinen A; van Staa TP; de Vries F; De Bruin ML
Acta Oncol; 2016 Jul; 55(7):851-8. PubMed ID: 27150973
[TBL] [Abstract][Full Text] [Related]
95. Comparative effectiveness research and its utility in In-clinic practice.
Dang A; Kaur K
Perspect Clin Res; 2016; 7(1):9-14. PubMed ID: 26955571
[TBL] [Abstract][Full Text] [Related]
96. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.
Lund JL; Richardson DB; Stürmer T
Curr Epidemiol Rep; 2015 Dec; 2(4):221-228. PubMed ID: 26954351
[TBL] [Abstract][Full Text] [Related]
97. Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.
Bronsveld HK; ter Braak B; Karlstad Ø; Vestergaard P; Starup-Linde J; Bazelier MT; De Bruin ML; de Boer A; Siezen CL; van de Water B; van der Laan JW; Schmidt MK
Breast Cancer Res; 2015 Aug; 17(1):100. PubMed ID: 26242987
[TBL] [Abstract][Full Text] [Related]
98. Importance of Beta Cell Function for the Treatment of Type 2 Diabetes.
Saisho Y
J Clin Med; 2014 Aug; 3(3):923-43. PubMed ID: 26237486
[TBL] [Abstract][Full Text] [Related]
99. Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells.
ter Braak B; Wink S; Koedoot E; Pont C; Siezen C; van der Laan JW; van de Water B
Breast Cancer Res; 2015 Jul; 17(1):97. PubMed ID: 26187749
[TBL] [Abstract][Full Text] [Related]
100. Type 2 diabetes pharmacoepidemiology update 2014: safety versus efficacy.
Singh S
Curr Diab Rep; 2014 Dec; 14(12):563. PubMed ID: 25363547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
